Table 4 The main PK parameters (Day 19) in NSCLC patients after a multiple oral dose of MET306 tablets at different doses
Dose group (mg) | n | Cmax (ng mL−1) | Tmax (h) | T1/2 (h) | AUC0−t (ng h mL−1) | AUC0−∞ (ng h mL−1) | VD/F (L) | CL/F (L h−1) |
|---|---|---|---|---|---|---|---|---|
10 | 1 | 11 | 6 | 30.2 | 323 | 362 | 2586 | 59.4 |
20 | 3 | 37.6 ± 11.6 | 5.00 ± 0.00 | 29.6 ± 1.95 | 1116 ± 357 | 1242 ± 413 | 1561 ± 494 | 37.0 ± 13.4 |
30 | 3 | 62.5 ± 22.4 | 4.67 ± 1.53 | 30.3 ± 2.88 | 1850 ± 970 | 2083 ± 1120 | 1577 ± 670 | 37.1 ± 19.3 |
45 | 3 | 73.1 ± 19.5 | 3.67 ± 1.15 | 28.0 ± 1.96 | 2177 ± 329 | 2381 ± 327 | 1561 ± 355 | 38.4 ± 6.25 |
60 | 4 | 90.4 ± 43.9 | 3.67 ± 2.08 | 27.9 ± 3.00 | 2983 ± 1996 | 3308 ± 2281 | 1979 ± 990 | 51.3 ± 30.2 |
80 | 4 | 166.6 ± 57.9 | 4.33 ± 3.51 | 29.6 ± 1.8 | 4393 ± 1281 | 4916 ± 1536 | 1430 ± 247 | 33.8 ± 7.3 |
105 | 5 | 184.4 ± 78.1 | 4.66 ± 1.52 | 28.35 ± 2.00 | 4843 ± 2242 | 5327 ± 2504 | 1837 ± 857 | 45.7 ± 24.1 |
140 | 1 | 194.2 | 2.98 | 30.2 | 4740 | 5162 | 2052 | 50.8 |